Drug Delivery

Testing for Other Drug Delivery Devices

Fit-for-purpose testing of dose, formulation, and stability for non-standard drug delivery formats.

ARE Labs matches controlled actuation, collection fixtures, environmental conditioning, and HPLC, ELISA, qPCR, or ddPCR quantitation to the device and formulation.

ISO 17025USP <601>USP <1601>ICH Q1AReviewed 2026-05-17
Request a quoteSubmit a sample

Testing specialty drug delivery devices

Specialty drug delivery device testing helps teams evaluate emerging, custom, and accessory-driven formats that do not fit neatly into an inhaler, nebulizer, nasal spray, or package category. USP <601>, USP <1601>, FDA drug-device guidance, and ICH Q1A provide a framework for common endpoints, including emitted dose, formulation behavior, and stability-linked performance. This testing is useful when:

  1. USP <601> dose collection compares emitted output across custom actuators, reservoirs, fill levels, or operating modes before design lock.
  2. FDA drug-device planning needs formulation-device compatibility data tied to HPLC, ELISA, qPCR, or ddPCR assay recovery.
  3. ICH Q1A storage pulls track API, impurity, dose, and device-function drift after temperature, humidity, or transport stress.
  4. USP <1601> or ISO 20072 concepts guide fit-for-purpose actuation, collection, and dose-uniformity setup for unusual delivery geometries.

Use this page when the device requires a defensible testing plan rather than a generic product description. ARE Labs defines the fixture, actuation sequence, collection endpoint, assay, and stability condition around the decision the data must support.

Core test menu for specialty delivery devices

Most non-standard delivery programs begin with dose output, formulation support, and stability trending. Aerosol sizing is added only when the delivery route or intended claim makes particle size a material endpoint.

Test method options

MethodStrengthsTradeoffAligned with
Fit-for-purpose emitted dose and uniformity
  • Custom collection fixtures quantify emitted dose, delivered dose, and device-to-device variability under USP <601> logic.
  • Assay recovery links collected output to active-specific HPLC, ELISA, qPCR, or ddPCR results.
Fixture feasibility and extraction recovery must be resolved before pivotal dose comparisons can be interpreted.
USP <601>USP <1601>
Formulation-device compatibility screen
  • Formulation screens compare excipients, solvents, suspensions, powders, or process variables against ICH Q8/Q9/Q10 development logic.
  • Paired chemistry and output data identify adsorption, viscosity, settling, degradation, or delivery-loss drivers.
Screening narrows candidates; it does not replace final device verification or clinical performance evidence.
ICH Q8/Q9/Q10
Stability-linked performance and chemistry pulls
  • ICH Q1A pull points connect storage condition, API drift, impurity profile, and dose output in one study file.
  • Post-stress testing can compare pre/post device behavior after conditioning or transport exposure.
Study duration follows storage design; method feasibility should be completed before samples enter conditioning.
ICH Q1AASTM D4169
Route-dependent aerosol sizing add-on
  • PSD or APSD can be added when FDA route, deposition, inhalation, or exposure questions make particle size material.
  • Sizing data can be paired with dose or formulation outputs so screens remain tied to device performance.
Particle sizing is not automatically relevant; non-aerosol devices should stay focused on dose, chemistry, and stability.
FDA MDI / DPI / nasal

Setup configurations

Specialty drug delivery studies begin with the device mechanism, not a preset method. Study planning defines a single delivered use, the output collection point, the actuation procedure, relevant formulation variables, and the handling of storage or stress states. These decisions determine the replicate structure, assay plan, controls, and acceptance logic.

Device interfaces

Custom holders, adapters, reservoirs, mouthpiece or outlet fixtures, collection media, extraction vessels, and containment selected for the actual delivery geometry.

Actuation profiles

Force, stroke, timing, orientation, priming, fill level, dose count, dwell time, and user-step simulation documented per run.

Formulation state

Solution, suspension, powder, biologic, nucleic acid, solvent, preservative, viscosity, pH, osmolality, and handling state defined before testing.

Conditioning states

Temperature, humidity, transport stress, storage orientation, pull schedule, preconditioning, and post-stress handling linked to the study question.

Controls & replicates

Device count, actuation count, blanks, media controls, comparators, and replicate count sized to expected variability and assay sensitivity.

Quality frame for specialty delivery studies

Even non-standard device work requires a defined quality posture before feasibility testing begins. These anchors determine how method controls, compendial logic, stability records, and final reporting are documented.

  • ISO 17025AccreditedTraceable calibration, method control, data review, and uncertainty documentation.
  • USP <601>AccreditedCompendial dose and aerosol-performance logic applied where relevant.
  • USP <1601>AlignedInhalation and nasal product characterization concepts used where they fit.
  • ICH Q1AAlignedStorage conditions, pull timing, and stability trend interpretation.

Key data outputs & reporting

Specialty drug delivery programs receive endpoint-specific datasets that connect the custom test setup to measured performance. Outputs may include emitted-dose statistics, formulation chemistry, assay recovery, stability trends, fixture notes, and QA/QC controls. Reports can support development review, method justification, change control, or regulatory-support files. Programs involving comparability, transport stress, or stability pulls may include additional deliverables.

Primary outputs

  • Emitted dose, delivered dose, shot-to-shot variability, device-to-device variability, and condition-based summary statistics.
  • Assay, impurity, recovery, pH, osmolality, formulation observation, and compatibility data where chemistry endpoints are included.
  • Stability pull-point tables and trend plots comparing pre/post conditioning, storage, or stress states.
  • Fixture, actuation, collection, extraction, calibration, control, and deviation records tied to each reported endpoint.

Deliverables

#FormatContents
01PDF reportMethods, setup, controls, deviations, results, and interpretation limits.
02CSV / XLSX datasetsDose statistics, chemistry tables, stability pulls, and condition summaries.
03FiguresTrend plots, pre/post comparisons, and setup diagrams when useful.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Comparability appendix — Side-by-side dose, chemistry, and condition summaries for reference or design-change review.
  • Stability trend pack — Pull-point tables and figures showing dose, assay, impurity, and device-function drift.
  • Transport-stress note — Conditioning exposure, handling observations, and post-stress performance changes summarized for packaging decisions.

QA / QC & data integrity

Custom device studies require defined QA/QC rules before the fixture is built. Controls run alongside sample collection so dose, chemistry, and stability data remain traceable from sample receipt through the final report. The study file documents method assumptions, invalid runs, storage state, assay suitability, and contributors to uncertainty rather than leaving them as informal notes.

Method blanks, collection-media controls, comparator devices, and condition controls defined by endpoint.

Balances, flow meters, chambers, timers, actuation fixtures, and analytical systems checked or calibrated before use.

HPLC, ELISA, qPCR, or ddPCR runs include standards, recovery checks, and suitability criteria where relevant.

Chain of custody covers devices, formulations, conditioned units, collected media, extracts, raw files, and analyst observations.

Predefined replicate rules, acceptance criteria, deviation handling, and outlier logic included in the protocol.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
QualityDocumented study records
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

Quick answers to questions specialty drug delivery teams ask when the device does not fit a standard inhaler, nebulizer, nasal, or package workflow. These answers cover method selection, sample planning, formulation links, stability pulls, deliverables, and scope boundaries. Most programs still need fixture, collection, and assay decisions during study planning before samples arrive at intake.

Q.How do we choose the first test?
A.Begin with the decision the data must support. Dose testing evaluates output consistency, formulation support addresses composition and assay questions, and stability testing measures changes during storage or stress. Aerosol sizing is added only when particle size is a material endpoint.
Q.Can ARE Labs build a custom fixture?
A.Yes. Specialty delivery studies often need custom holders, adapters, collection media, or actuation controls. Feasibility work confirms the setup before pivotal comparisons or stability pulls begin.
Q.Can formulation work be paired with dose testing?
A.Yes. Formulation screens can be paired with emitted dose, assay recovery, impurity checks, pH, osmolality, and physical observations. This connects composition choices to measured device output.
Q.How many devices or actuations are needed?
A.Device count, actuation count, fill states, storage pulls, and replicate count depend on expected variability, assay sensitivity, and the decision the study must support. Final counts are set during protocol development.
Q.What data will I receive?
A.Deliverables may include dose statistics, chemistry tables, stability trend plots, setup notes, calibration and control records, deviations, a PDF report, and CSV or XLSX datasets.
Q.Does this cover complete regulatory approval?
A.No. ARE Labs provides defined testing and supporting documentation. This page does not claim clinical testing, software validation, electrical safety, biocompatibility, product certification, or full submission management.

Standards & guidance

Other drug delivery device studies are designed around the delivery mechanism and the regulatory framework that best fits the product. ARE Labs identifies accredited work as accredited and describes other references as aligned or conformant where applicable. The rows below address dose output, formulation development, stability, and route-dependent aerosol characterization commonly cited in fit-for-purpose study plans.

Inhalation & Drug Delivery - Accredited

USP <601>

Dose collection and aerosol performance logic for inhalation and spray drug productsView standard ->Inhalation & Drug Delivery - Aligned

USP <1601>

Characterization concepts for inhalation and intranasal products used where applicableView standard ->QA & Regulatory - Aligned

ICH Q8/Q9/Q10

Pharmaceutical development, quality risk management, and formulation control strategyView standard ->QA & Regulatory - Aligned

ICH Q1A

Storage conditions, pull timing, and stability trend interpretation for drug productsView standard ->Packaging & Stability - Aligned

ASTM D4169

Distribution-cycle conditioning before post-stress device performance or package evaluationView standard ->QA & Regulatory - Aligned

FDA MDI / DPI / nasal

Quality considerations for inhalation and nasal drug products when route-dependent endpoints applyView standard ->

Related testing services

Test

Dose Uniformity & Emitted Dose

Core output test for custom drug delivery formats where actuation, fill state, reservoir design, or geometry may change delivered dose.Read more ->Test

Pharma Formulation Support

Pairs composition, excipient, process, and assay work with delivery performance for solution, suspension, powder, or biologic candidates.Read more ->Test

Stability and Accelerated Aging

Links storage, humidity, temperature, and transport stress to post-conditioning dose, chemistry, and device-function changes.Read more ->Test

Particle Size Distribution (PSD) Testing

Accurate add-on when the specialty device aerosolizes drug product and route, deposition, or exposure depends on particle size.Read more ->